B 細胞淋巴瘤的標的治療-抗CD20 單株抗體rituximab (Mabthera) 以細胞表面標記做為標的治療是目前腫瘤治療的新趨勢,除了可對腫療發揮更專一之 療效外,對正常組織之傷害也可至最低,Rituximab(Mabthera?是針對B細胞特有 ...
Rituximab, an Anti-CD20 Monoclonal Antibody: History & Mechanism CD20 is an integral membrane protein that crosses the cell membrane four times. Rituximab is a chimeric monoclonal antibody with the Fab portion coming from ...
MABTHERA500MG(高劑量) - 【篤實關懷倫理卓越】光田綜合醫院 ... 商品名, MABTHERA☆500MG(高劑量), 藥品許可證, 衛署菌疫輸字第000928號 ... Rituximab是嫁接(chimeric)鼠/人單株抗體,特別與橫跨膜(transmembrane) ...
MABTHERA100MG(低劑量) - 【篤實關懷倫理卓越】光田綜合醫院 ... 商品名, MABTHERA☆100MG(低劑量), 藥品許可證, 衛署菌疫輸字第000928號 ... Rituximab是嫁接(chimeric)鼠/人單株抗體,特別與橫跨膜(transmembrane) ...